LUC00308I2 - - Google Patents

Info

Publication number
LUC00308I2
LUC00308I2 LU00308C LUC00308C LUC00308I2 LU C00308 I2 LUC00308 I2 LU C00308I2 LU 00308 C LU00308 C LU 00308C LU C00308 C LUC00308 C LU C00308C LU C00308 I2 LUC00308 I2 LU C00308I2
Authority
LU
Luxembourg
Application number
LU00308C
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47215803&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00308(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of LUC00308I2 publication Critical patent/LUC00308I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LU00308C 2011-11-16 2023-05-31 LUC00308I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161560554P 2011-11-16 2011-11-16
US201261644111P 2012-05-08 2012-05-08
US201261713713P 2012-10-15 2012-10-15

Publications (1)

Publication Number Publication Date
LUC00308I2 true LUC00308I2 (fr) 2025-09-22

Family

ID=47215803

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00308C LUC00308I2 (fr) 2011-11-16 2023-05-31

Country Status (41)

Country Link
US (4) US9023995B2 (fr)
EP (2) EP3536710B1 (fr)
JP (3) JP6289375B2 (fr)
KR (3) KR102159109B1 (fr)
CN (5) CN112812183B (fr)
AP (1) AP2014007571A0 (fr)
AR (1) AR089178A1 (fr)
AU (1) AU2012339734B2 (fr)
BR (1) BR112014011594B1 (fr)
CA (1) CA2852994C (fr)
CL (1) CL2014001123A1 (fr)
CO (1) CO7020871A2 (fr)
CY (2) CY1122278T1 (fr)
DK (2) DK2780373T3 (fr)
EA (1) EA031948B1 (fr)
EC (1) ECSP14004976A (fr)
ES (2) ES2755732T3 (fr)
FI (2) FI3536710T3 (fr)
FR (1) FR23C1023I2 (fr)
GE (1) GEP20186816B (fr)
HR (2) HRP20251675T1 (fr)
HU (2) HUE047437T2 (fr)
IL (2) IL232100B (fr)
LT (3) LT2780373T (fr)
LU (1) LUC00308I2 (fr)
MX (1) MX347164B (fr)
MY (1) MY195289A (fr)
NL (1) NL301233I2 (fr)
NO (2) NO2023024I1 (fr)
PE (1) PE20142041A1 (fr)
PH (1) PH12014501108B1 (fr)
PL (1) PL2780373T3 (fr)
PT (2) PT3536710T (fr)
RS (2) RS59248B1 (fr)
SG (1) SG11201402283PA (fr)
SI (1) SI2780373T1 (fr)
TW (1) TWI573804B (fr)
UA (1) UA115540C2 (fr)
UY (1) UY34456A (fr)
WO (1) WO2013074569A1 (fr)
ZA (1) ZA201402491B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3252076B1 (fr) 2011-01-14 2019-09-04 The Regents Of The University Of California Utilisation diagnostique d' anticorps thérapeutiques contre la protéine ror-1
FI3536710T3 (fi) 2011-11-16 2026-01-14 Boehringer Ingelheim Int Anti-il-36r -vasta-aineita
EP3093294A1 (fr) 2012-02-24 2016-11-16 Stemcentrx, Inc. Anticorps anti dll3 et procédés d'utilisation
TWI777174B (zh) * 2014-03-14 2022-09-11 瑞士商諾華公司 針對lag-3之抗體分子及其用途
RU2582569C2 (ru) * 2014-07-24 2016-04-27 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека, днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека с с-концевым полигистидиновым тагом, плазмидный экспрессионный вектор (варианты), штамм бактерий escherichia coli bl21 star[de3] (рет-il36raf), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 и штамм бактерий escherichia coli bl21 star[de3] (pet-il36raf-his), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 с с-концевым полигистидиновым тагом
CN107847589B (zh) 2015-04-01 2022-03-29 安奈普泰斯生物有限公司 针对t细胞免疫球蛋白和粘蛋白蛋白3(tim-3)的抗体
PL3283110T3 (pl) * 2015-04-15 2022-06-27 Anaptysbio, Inc. Przeciwciała skierowane przeciwko receptorowi interleukiny 36 (il-36r)
WO2016201282A2 (fr) * 2015-06-12 2016-12-15 Ludwig Institute For Cancer Research Ltd Anticorps spécifiques de tgf-bêta 3 et procédés et utilisations associés
JP6654773B2 (ja) * 2015-12-25 2020-02-26 国立大学法人名古屋大学 インターロイキン３６受容体アンタゴニスト欠損症の治療薬
BR112019008861A2 (pt) 2016-11-01 2019-07-09 Tesaro, Inc. anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3)
SG10201913083SA (en) 2017-01-09 2020-03-30 Tesaro Inc Methods of treating cancer with anti-tim-3 antibodies
JP2020512344A (ja) * 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
MA50424A (fr) * 2018-01-08 2020-08-26 Chemocentryx Inc Méthodes de traitement du psoriasis pustuleux généralisé avec un antagoniste de ccr6 ou cxcr2
WO2019177883A2 (fr) * 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Utilisation d'anticorps anti-il-36 r pour le traitement d'une maladie intestinale inflammatoire
WO2019177888A1 (fr) * 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Utilisation d'anticorps anti-il-36r pour le traitement du psoriasis pustuleux généralisé
WO2020018503A2 (fr) * 2018-07-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Anticorps anti-il36r
HRP20240999T1 (hr) 2018-07-16 2024-10-25 Regeneron Pharmaceuticals, Inc. Glodavački modeli bolesti ditra i njihova upotreba
CN112638946A (zh) 2018-08-16 2021-04-09 坎塔吉亚有限责任公司 抗il1rap抗体组合物
TW202019958A (zh) * 2018-09-28 2020-06-01 日商協和麒麟股份有限公司 Il-36抗體及其用途
EP3898673A1 (fr) * 2018-12-21 2021-10-27 23Andme, Inc. Anticorps anti-il-36 et leurs procédés d'utilisation
AU2019416727A1 (en) * 2018-12-27 2021-07-22 Boehringer Ingelheim International Gmbh Anti-il-36R antibodies for treatment of palmoplantar pustulosis
KR20210137520A (ko) * 2019-03-08 2021-11-17 베링거 인겔하임 인터내셔날 게엠베하 항-il-36r 항체 제형
JP7811772B2 (ja) * 2019-12-05 2026-02-06 学校法人東京薬科大学 筋組織の減少を抑制するための組成物
AR120913A1 (es) * 2019-12-27 2022-03-30 Teijin Pharma Ltd Anticuerpo que inhibe específicamente la señalización de il-36r
EP4153233A1 (fr) 2020-05-19 2023-03-29 Boehringer Ingelheim International GmbH Anticorps anti-il-36r pour le traitement des dermatites atopiques
JP7812364B2 (ja) 2020-07-17 2026-02-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 好中球性皮膚症の処置のための抗ｉｌ－３６ｒ抗体
WO2022026832A1 (fr) 2020-07-30 2022-02-03 Anaptysbio, Inc. Thérapie contre l'ichtyose à anti-récepteur de l'interleukine 36 (il-36r)
WO2022026829A1 (fr) 2020-07-30 2022-02-03 Anaptysbio, Inc. Thérapie anti-récepteur de l'interleukine 36 (il-36r) pour traiter la toxicité cutanée
CA3192882A1 (fr) 2020-09-30 2022-04-07 Boehringer Ingelheim International Gmbh Anticorps anti-il-36r pour le traitement de la douleur inflammatoire chronique
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
WO2022127842A1 (fr) * 2020-12-17 2022-06-23 上海华奥泰生物药业股份有限公司 Anticorps bispécifique ciblant il-17a et il-36r et son application
WO2022150644A1 (fr) 2021-01-08 2022-07-14 Anaptysbio, Inc. Thérapie contre l'acné par récepteur de l'interleukine 36 (il-36r)
WO2022150642A1 (fr) 2021-01-08 2022-07-14 Anaptysbio, Inc. Thérapie anti-récepteur de l'interleukine 36 (il-36r) contre la maladie de verneuil
WO2022166977A1 (fr) * 2021-02-08 2022-08-11 上海普铭生物科技有限公司 Anticorps anti-il-36r humain et son application
EP4301409A1 (fr) 2021-03-04 2024-01-10 Boehringer Ingelheim International GmbH Procédés de traitement du ppg
WO2022192531A2 (fr) 2021-03-12 2022-09-15 Boehringer Ingelheim International Gmbh Biomarqueurs associés au traitement par anticorps anti-il-36 r dans le psoriasis pustuleux généralisé
BR112023017717A2 (pt) * 2021-05-03 2024-01-09 Boehringer Ingelheim Int Método para produção de espesolimabe
EP4357361A4 (fr) * 2021-06-18 2025-09-03 Chia Tai Tianqing Pharmaceutical Group Co Ltd Anticorps anti-il-36r et son utilisation
EP4370550A1 (fr) 2021-07-12 2024-05-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d'inhibiteurs d'il-36 permettant le traitement du syndrome de netherton
US20230049147A1 (en) 2021-08-13 2023-02-16 Boehringer Ingelheim International Gmbh Anti-il-36r antibodies for the treatment of a fibrotic condition
EP4409592A2 (fr) 2021-09-28 2024-08-07 Boehringer Ingelheim International Gmbh Système et méthode d'évaluation de la gravité de dermatoses neutrophiles avec manifestation cutanée visible
TW202334200A (zh) 2021-10-28 2023-09-01 美商艾伯維有限公司 抗澱粉樣蛋白β抗體及其使用方法
TW202323293A (zh) * 2021-10-29 2023-06-16 新加坡商創響私人有限公司 新型抗ｉｌ－３６ｒ抗體
CN115724975A (zh) * 2022-10-20 2023-03-03 江苏荃信生物医药股份有限公司 抗人白介素36受体单克隆抗体及其应用
CN116574189A (zh) 2023-01-30 2023-08-11 北京智仁美博生物科技有限公司 针对人il-36r和/或人il-1r3的多种抗体及其用途
WO2024175031A1 (fr) 2023-02-21 2024-08-29 江苏恒瑞医药股份有限公司 Protéine de liaison à il-36r et son utilisation médicinale
JP2026507877A (ja) 2023-03-09 2026-03-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 化膿性汗腺炎（ｈｓ）を処置するための抗ｉｌ－３６ｒ抗体の使用
KR20260025132A (ko) 2023-06-09 2026-02-23 베링거 인겔하임 인터내셔날 게엠베하 전신 농포성 건선(gpp)의 치료 및 예방 방법

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (fr) 1979-10-18 1981-04-30 Univ Illinois Medicaments "pro-drugs" pouvant etre actives par des enzymes hydrolytiques
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (fr) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Vecteurs de transformation de la levure yarrowia
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0940468A1 (fr) 1991-06-14 1999-09-08 Genentech, Inc. Domaine variable d'un anticorps humanisé
DK0656789T3 (da) 1992-08-21 1998-08-24 Genentech Inc Fremgangsmåde til behandling af en LFA-1-medieretforstyrrelse.
EP1005870B1 (fr) 1992-11-13 2009-01-21 Biogen Idec Inc. Application thérapeutique d'anticorps chimériques et radio-marqués contre l'antigène à différentiation restreinte des lymphocytes B humains pour le traitement du lymphome des cellules B
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US6416973B1 (en) 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
ATE523593T1 (de) 1997-08-01 2011-09-15 Schering Corp Membranproteine aus säugetierzellen und verwandte reagentien
ES2637801T3 (es) * 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
EP1627927A3 (fr) * 2001-03-01 2006-06-07 Epigenomics AG Méthode, système et programme informatique permettant de déterminer l'effet biologique et/ou l'activité de médicaments, de substances chimiques et/ou compositions pharmaceutiques en fonction de leur effet sur l'état de méthylation de l'ADN.
WO2004031362A2 (fr) * 2002-10-03 2004-04-15 Large Scale Biology Corporation Ingenierie des proteines multimeriques
EP2500352A1 (fr) * 2005-08-19 2012-09-19 Abbott Laboratories Immunoglobuline à double domaine variable et ses utilisations
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US8034771B2 (en) * 2006-09-08 2011-10-11 Amgen Inc. IL-1F6 polypeptides
MX2009011500A (es) 2007-04-23 2010-01-29 Schering Corp Anticuerpos anti-mdl-1.
AU2008270710A1 (en) 2007-06-29 2009-01-08 Merck Sharp & Dohme Corp. MDL-1 uses
RU2011105466A (ru) * 2008-08-28 2012-10-10 ВАЙЕТ ЭлЭлСи (US) Применения цитокинов семейств il-22, il-17 и il-1 при аутоиммунных заболеваниях
FI3536710T3 (fi) 2011-11-16 2026-01-14 Boehringer Ingelheim Int Anti-il-36r -vasta-aineita
PL3283110T3 (pl) 2015-04-15 2022-06-27 Anaptysbio, Inc. Przeciwciała skierowane przeciwko receptorowi interleukiny 36 (il-36r)

Also Published As

Publication number Publication date
AU2012339734A1 (en) 2014-04-24
CN118496365A (zh) 2024-08-16
ECSP14004976A (es) 2015-11-30
US20200231684A1 (en) 2020-07-23
AP2014007571A0 (en) 2014-04-30
CN112812183B (zh) 2024-06-11
JP6719490B2 (ja) 2020-07-08
HRP20191835T1 (hr) 2019-12-27
FR23C1023I1 (fr) 2023-07-21
JP6289375B2 (ja) 2018-03-07
CO7020871A2 (es) 2014-08-11
CN104080808A (zh) 2014-10-01
KR20190122877A (ko) 2019-10-30
EP3536710A1 (fr) 2019-09-11
CN112812183A (zh) 2021-05-18
KR20140101738A (ko) 2014-08-20
KR102038310B1 (ko) 2019-11-01
FR23C1023I2 (fr) 2024-03-29
RS59248B1 (sr) 2019-10-31
SI2780373T1 (sl) 2019-12-31
MX347164B (es) 2017-04-18
EP3536710B1 (fr) 2025-10-29
CA2852994A1 (fr) 2013-05-23
RS67639B1 (sr) 2026-02-27
IL232100B (en) 2020-04-30
HUE047437T2 (hu) 2020-04-28
NL301233I2 (nl) 2023-09-13
AU2012339734B2 (en) 2017-02-16
NO2025001I1 (no) 2025-01-03
LT2780373T (lt) 2019-09-25
HUS2300021I1 (hu) 2023-07-28
JP2018093885A (ja) 2018-06-21
PT2780373T (pt) 2019-11-27
JP2020156506A (ja) 2020-10-01
MX2014005759A (es) 2014-09-08
TW201333037A (zh) 2013-08-16
US20240409648A1 (en) 2024-12-12
UY34456A (es) 2013-05-31
DK3536710T3 (da) 2026-01-19
CN104080808B (zh) 2016-11-16
KR102159109B1 (ko) 2020-09-23
US20150203584A1 (en) 2015-07-23
BR112014011594B1 (pt) 2021-11-09
PT3536710T (pt) 2026-01-20
GEP20186816B (en) 2018-02-12
CY2023014I1 (el) 2023-11-15
UA115540C2 (uk) 2017-11-27
LTPA2023518I1 (fr) 2023-06-12
US20130236471A1 (en) 2013-09-12
BR112014011594A2 (pt) 2017-07-04
CY2023014I2 (el) 2023-11-15
PL2780373T3 (pl) 2020-03-31
NZ623425A (en) 2015-12-24
FIC20230020I1 (fi) 2023-06-01
EA201400579A1 (ru) 2014-10-30
US10550189B2 (en) 2020-02-04
MY195289A (en) 2023-01-12
CA2852994C (fr) 2023-02-14
WO2013074569A1 (fr) 2013-05-23
CL2014001123A1 (es) 2015-01-23
LT3536710T (lt) 2026-01-26
ES2755732T3 (es) 2020-04-23
EP2780373A1 (fr) 2014-09-24
ZA201402491B (en) 2021-09-29
AR089178A1 (es) 2014-08-06
CN107007833B (zh) 2020-12-11
EP2780373B1 (fr) 2019-08-21
PE20142041A1 (es) 2014-12-18
NL301233I1 (fr) 2023-06-07
PH12014501108A1 (en) 2014-08-04
FI3536710T3 (fi) 2026-01-14
CY1122278T1 (el) 2020-11-25
IL232100A0 (en) 2014-05-28
DK2780373T3 (da) 2019-11-04
US20170298135A9 (en) 2017-10-19
SG11201402283PA (en) 2014-06-27
KR20200110476A (ko) 2020-09-23
LTC2780373I2 (fr) 2024-11-11
NO2023024I1 (no) 2023-05-30
CN118515766A (zh) 2024-08-20
IL272035A (en) 2020-02-27
EA031948B1 (ru) 2019-03-29
HRP20251675T1 (hr) 2026-02-13
CN107007833A (zh) 2017-08-04
ES3058874T3 (en) 2026-03-13
PH12014501108B1 (en) 2014-08-04
US9023995B2 (en) 2015-05-05
TWI573804B (zh) 2017-03-11
JP2015500633A (ja) 2015-01-08

Similar Documents

Publication Publication Date Title
LTC2780373I2 (fr)
BR112013022641A2 (fr)
BR112013031251A2 (fr)
BR112013027245A2 (fr)
BR112013024383A2 (fr)
BR112013026905A2 (fr)
BR112013023185A2 (fr)
BR112013022995A2 (fr)
BR112013017670A2 (fr)
BR112013027830A2 (fr)
BR112013026744A2 (fr)
AP3853A (fr)
BR112013023927A2 (fr)
BR112013027452A2 (fr)
BR112013024365A2 (fr)
BR112013027121A2 (fr)
AP2016009466A0 (fr)
BR112013024588A2 (fr)
BR112013031556A2 (fr)
BR112013026790A2 (fr)
BR112013032366A2 (fr)
BR112013032377A2 (fr)
BR112013032380A2 (fr)
BR112013027836A2 (fr)
BR112013018949A2 (fr)